



JOINT OPEN
COMMITTEE MEETING
WORKING LANGUAGE: RUSSIAN

24 November 2025 15:00 – 18:00 JOINT OPEN AEB SUSTAINABILITY AND AEB ENERGY COMMITTEES MEETING

Moscow School of Management SKOLKOVO, ul. Novaya, d. 100, Belu-Orizonte Hall

SUSTAINABLE DEVELOPMENT IN THE PHARMACEUTICAL INDUSTRY

PROGRAMME

MODERATOR

Roman ISHMUKHAMETOV, Chairman of the AEB Sustainability Committee, Senior Lawyer, "Melling, Voitishkin and Partners"

15:30 – 16:00 Guest registration, welcome coffee

16:00 – 16:10 WELCOME ADDRESS

Tadzio SCHILLING, AEB CEO

16:10 – 16:40 KEYNOTE INTERVENTION

"SUSTAINABILITY" IN PHARMA: WHAT IS IT AND WHERE IS THE LINE WITH "BUSINESS AS USUAL"

Elena DUBOVITSKAYA, Director of the Sustainability Centre, SKOLKOVO School of Management

Marina VELDANOVA, Professor of Business Practice, Director of the Healthcare Developmen Centre, SKOLKOVO School of Management, MD, PhD

16:40 – 17:10 PRESENTATIONS BY PHARMACEUTICAL COMPANIES

HOW "SUSTAINABILITY" IS MANIFESTED AT DIFFERENT STAGES OF THE VALUE CREATION PROCESS

Valeria LEMESHKO, Head of the Department for Healthcare Development and Interaction with Federal Government Authorities, Roche-Moscow

Irina ASHRAPOVA, Head of EHS & Sustainability, AstraZeneca Russia & Eurasia – Sustainability at AstraZeneca

Ekaterina CHULKOVA, Senior Corporate Social Responsibility Manager, Servier

Ekaterina SIDOROVA, Head of Sustainable Development Department, BIOCAD

POINTS FOR DISCUSSION

1. Sustainable development in the pharmaceutical product value chain. "Corporate purpose" and "societal value" of pharmaceutical companies.

Does "sustainability" create additional value for pharmaceutical companies, their patients and other stakeholders? What financial and non-financial benefits do companies in this industry gain from implementing sustainable practices? Which elements of "sustainability" in the pharmaceutical product value chain are most critical and why?

2. Features of sustainable development in the pharmaceutical industry in Russia.

What are the specifics of corporate sustainable development practices of pharmaceutical companies in Russia, including in the context of national development goals and state-promoted tools such as the ESG rating, the Standard of Public Capital of Business and the Ministry of Economic Development's Sustainable Development Reporting Standard?

3. Practical examples of pharmaceutical companies' initiatives in the field of sustainable development in Russia and the contribution of such initiatives to the achievement of national development goals.

How does the pharmaceutical industry contribute to the achievement of Russia's national development goals and sustainable socio-economic development of the country? What additional mechanisms of state support could give impetus to the further development of sustainable practices in the industry?

4. Opportunities for consolidation of resources of pharmaceutical companies for the joint implementation of "sustainable" projects, taking into account national development goals.

What directions and formats of joint projects of pharmaceutical companies can enhance their contribution to public welfare?

17:10 – 17:25 COMMENTS FROM INVITED EXPERTS

Vladimir GORCHAKOV, Director, Sustainable Development Risk Assessment Group, ACRA

Ekaterina KUZMINA, Vice President, Director for Development, PSB, Chairman of the Exper Council of the ESG rating

17:25 – 17:55 Q&A, COMMENTS FROM THE AUDIENCE AND DISCUSSION

17:55 - 18:00 CLOSING REMARKS

Working language Russian. Interpretation will not be provided.

Contact Persons REGISTRATION: Polina Skorovarova, AEB Events Coordinator, +7 965-216-43-59, polina.skorovarova@aebrus.ru

PROGRAMME: Julia Gavrikova, AEB Committees Coordinator, tel.: +7 (916) 555-72-70 julia.gavrikova@aebrus.ru

Mikhail Podelyakin, AEB Committees Coordinator, tel.: +7 (906) 057-32-47, mikhail.podelyakin@aebrus.ru





Отказ от ответственности

Информация, предоставленная в рамках вебинара, предназначена исключительно для личного использования. Участник вебинара принимает на себя полную ответственность за свои действия в рамках использования данной информации. Предоставленная информация носит общий характер и не должна рассматриваться как юридический, налоговый, бухгалтерский, консультационный или любой другой профессиональный совет. Во всех случаях, прежде чем принимать какие-либо решения, вы должны проконсультироваться со специалистами, знакомыми с лично вашей фактической ситуацией, обратиться к ним за советом по конкретным вопросам. АЕБ не несет ответственности и не будет нести никаких обязательств в отношении любых действий или бездействия, связанных с предоставленной информацией.